Harvard Medical School

11th Annual Emerging Trends in Workplace Wellness Conference Features National Speakers and Trending Topics

Retrieved on: 
Monday, March 11, 2024
Health, Harvard Medical School, Certification, Conference, Learning, Christian democracy, Ecosystem, Workforce, Workweek and weekend, SHRM, Pharmaceutical industry

BOSTON, March 11, 2024 /PRNewswire-PRWeb/ -- Wellness Workdays, a leading provider of workplace wellness programs, will host its 11th Annual Emerging Trends in Wellness Conference on April 11th. The event will feature nationally recognized speakers from across the country who highlight the importance of employee well-being, how to become a wellness employer of choice, and key strategies to develop a healthy and resilient workforce.

Key Points: 
  • Wellness Workdays' virtual conference features speakers from Columbia Construction, Culver Pediatrics, Idaho Forest Group, and Other Leading Industry Employers
    BOSTON, March 11, 2024 /PRNewswire-PRWeb/ -- Wellness Workdays, a leading provider of workplace wellness programs, will host its 11th Annual Emerging Trends in Wellness Conference on April 11th.
  • "As employee needs continue to evolve, employers now appreciate that wellness interventions are a critical strategic element to a thriving and resilient workforce," said Debra Wein, CEO of Wellness Workdays.
  • In addition to learning from leading industry employers, attendees will also learn from a panel of this year's certified Best Wellness Employers.
  • Wellness Workdays is recognized by SHRM to offer Professional Development Credits (PDCs) for the SHRM-CPSM or SHRM-SCPSM.

Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout

Retrieved on: 
Monday, March 11, 2024
JBC, Harvard Medical School, Genetics, Yeshiva University, SVP, Research, Senior, IND, Doctor of Philosophy, Drug development, Molecular biology, GLP, Fine chemical

At this time, Medicilon officially appoints Dr. Qingcong Lin as President of Medicilon USA Corp, a significant step to deepen its global and strategic layout.

Key Points: 
  • At this time, Medicilon officially appoints Dr. Qingcong Lin as President of Medicilon USA Corp, a significant step to deepen its global and strategic layout.
  • Effective March 1, 2024, Medicilon appointed Dr. Qingcong Lin as President of Medicilon USA Corp in Boston.
  • Dr. Qingcong Lin, President of Medicilon USA Corp., stated," I am honored to join Medicilon at this crucial development stage.
  • Dr. Chunlin Chen, Founder & CEO of Medicilon, said, "We are delighted to have Dr. Qingcong Lin join Medicilon.

ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University

Retrieved on: 
Monday, March 11, 2024
Discovery, Harvard Medical School, Research, Neurology, Ono Pharmaceutical, Drug discovery, Patient, Harvard University, Senior, OTD, Pharmaceutical industry

OSAKA, Japan, March 11, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University (Cambridge, MA, USA; "Harvard") aiming at validating novel therapeutic targets.

Key Points: 
  • OSAKA, Japan, March 11, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University (Cambridge, MA, USA; "Harvard") aiming at validating novel therapeutic targets.
  • Working together with Harvard's Office of Technology Development (OTD), Ono will support and fund research projects that are jointly selected.
  • With the combined expertise and resources of both Ono and Harvard, this strategic alliance will promote our innovative drug discovery efforts.
  • "We are pleased to work together with Harvard University, a leading institution developing cutting-edge technologies and advancing research through strategic alliances such as this one," stated Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research at Ono Pharmaceutical.

Aledade Appoints National Equity Expert to Board of Directors

Retrieved on: 
Monday, March 11, 2024
Organizational culture, Research, Racism, Global health, FACP, Diversity, Health, Tufts University, Dean (education), Patient, Internal medicine, Medicine, Knowledge, Health equity, Harvard Medical School, Workforce, Education, Nursing

Bethesda, MD, March 11, 2024 (GLOBE NEWSWIRE) -- Aledade , the nation’s largest network of independent primary care, has named a highly regarded diversity, equity and inclusion expert to its Board of Directors.

Key Points: 
  • Bethesda, MD, March 11, 2024 (GLOBE NEWSWIRE) -- Aledade , the nation’s largest network of independent primary care, has named a highly regarded diversity, equity and inclusion expert to its Board of Directors.
  • Joyce A. Sackey , M.D., FACP, Chief Equity, Diversity and Inclusion Officer and Associate Dean at Stanford Medicine, is the newest member of Aledade’s Board of Directors.
  • “We are grateful to have Dr. Sackey join our board and share her expertise with us,” said Farzad Mostashari, M.D., co-founder and CEO of Aledade.
  • “At Aledade, we are deeply committed to advancing equity and inclusion as part of our mission and core values.

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

Retrieved on: 
Monday, March 11, 2024
Ophthalmology, ASRS, APLS, Education, Retina, Union College, Faculty, Society, Health, Patient, Harvard Medical School, Research, Nursing

WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18.

Key Points: 
  • WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18.
  • “Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Retina Specialists (ASRS), so we are delighted to welcome him to the Apellis team,” said Caroline Baumal, M.D., Chief Medical Officer, Apellis.
  • “I was an early adopter of SYFOVRE and have realized first-hand how impactful this treatment is for GA patients.
  • Dr. Ferrone earned his undergraduate degree from Union College and his medical degree from Harvard Medical School.

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
Thursday, March 7, 2024
SAN, Neoplasm, Division, Research fellow, Immunotherapy, Colorectal cancer, Gastrointestinal cancer, Drug development, Mentorship, Clinical research, Pembrolizumab, CRC, MSS, National Cancer Institute, FACP, Preventive healthcare, Gene expression, NCCN, USC, Associate, Patient, Harvard Medical School, Oncology, George Washington University, Cancer, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

Retrieved on: 
Wednesday, March 6, 2024
Translational medicine, SAN, MD, Emergency medicine, Partnership, Atopic dermatitis, Asthma, Chronic obstructive pulmonary disease, Rutgers University, Formoterol, Associate, Patient, Disease, Constriction, Harvard Medical School, ASLN, Pharmaceutical industry

“I’m delighted to work with the ASLAN team on this exciting opportunity to evaluate development paths for eblasakimab in COPD, a Type 2-driven disease.

Key Points: 
  • “I’m delighted to work with the ASLAN team on this exciting opportunity to evaluate development paths for eblasakimab in COPD, a Type 2-driven disease.
  • In November 2023, ASLAN announced translational data from healthy donor tissue that suggested eblasakimab’s potential as a COPD therapeutic to inhibit Type 2 inflammation.
  • Further studies have been conducted using lung tissue from a COPD patient, comparing the same concentrations of eblasakimab and dupilumab.
  • Further translational data on eblasakimab in COPD will be submitted for publication at upcoming scientific congresses.

Sandoz announces nominations to the Board of Directors and leadership change

Retrieved on: 
Tuesday, March 5, 2024
Remco, J&J, Person, Chemistry, Mechanical, Growth, IMD, Swisscom, University, Lufthansa, Organization, 10x Genomics, Annual general meeting, Erasmus University Rotterdam, Johnson & Johnson, MBA, Gesellschaft mit beschränkter Haftung, Genomics, Retirement, Flexner Report, Harvard Medical School, HST, CFO, Massachusetts Institute of Technology, Merck, Harvard University, Executive Committee, Doctor of Philosophy, Annual, KPMG, Management

Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.

Key Points: 
  • Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.
  • I am pleased we can propose exceptional people in science and in business for election to the Board of Directors this year.
  • The new Board talent maintains the complementarity of expertise and experience in the areas relevant to Sandoz.
  • The following persons are recommended for election to the Board of Directors at the Annual General Meeting on April 30, 2024:

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

Retrieved on: 
Friday, March 1, 2024
EVS, Therapy, Aegle, Harvard Medical School, Exosome, NRX, AbbVie, Quality, University, Conference, Patient, Development, Seminal vesicles, CMC, Medical device

Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."

Key Points: 
  • Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."
  • Dr. Sarel joins a prestigious lineup of speakers including representatives from leading exosome companies, e.g.
  • The summit will take place on April 23-25, 2024 in Boston, MA.
  • To learn more about the summit and to register, please visit the Conference Website .

Ocugen Clinical Showcase Webcast Now Available

Retrieved on: 
Wednesday, February 28, 2024
Retinitis pigmentosa, RHO, Vaccine, University, Faculty, Event, Associate, Harvard Medical School, Mutation, Communication

MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Clinical Showcase webcast from the February 21, 2024 live event is now available in the Events & Presentations section of the Ocugen website.

Key Points: 
  • MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Clinical Showcase webcast from the February 21, 2024 live event is now available in the Events & Presentations section of the Ocugen website.
  • The showcase replay includes more detail on the Phase 3 study design for OCU400, as well as market potential for this first-in-class product candidate.
  • The panel discussion offers first-hand experience from an OCU400 Phase 1/2 clinical trial patient with the RHO mutation who has completed 12 months of therapy and lead investigator, Dr. Byron Lam, Professor of Ophthalmology, Mark J.
  • Please direct any questions related to the webcast to Tiffany Hamilton, Head of Communications, at [email protected] .